<DOC>
	<DOC>NCT00237250</DOC>
	<brief_summary>The purpose of this study is to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to placebo in lowering post-meal blood glucose levels in people with pre-diabetes who have high blood sugar levels after meals.</brief_summary>
	<brief_title>Efficacy and Safety of Vildagliptin in Subjects With Impaired Glucose Tolerance</brief_title>
	<detailed_description />
	<mesh_term>Glucose Intolerance</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<criteria>Blood glucose criteria must be met Body mass index (BMI) in the range 2345 Diagnosis of diabetes Serious cardiovascular events within the past 6 months Use of insulin or any oral antidiabetic agent Other protocoldefined exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Pre-diabetes</keyword>
	<keyword>vildagliptin</keyword>
	<keyword>IGT</keyword>
</DOC>